NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-MD-21-022 from the NIH Guide for Grants and Contracts
Notice NOT-AA-21-028 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-076 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-075 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-074 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-229 from the NIH Guide for Grants and Contracts. Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including structural birth defects (SBDs), intellectual developmental disabilities (IDDs) and inborn errors of metabolism (IEMs). Large quantities of genomic data collected from pediatric birth defects cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening, functional validation and characterization of birth defects-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest.
Funding Opportunity RFA-HL-23-005 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The EIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The EIA will support the research program of NHLBI-funded investigators for up to seven years. The EIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the EIA must be within the scope of the NHLBI mission (http://www.nhlbi.nih.gov/about/org/mission).
Funding Opportunity RFA-HL-23-004 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The OIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. The OIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the OIA must be within the scope of the NHLBI mission (https://www.nhlbi.nih.gov/about/mission-statement). It is anticipated that the OIA will: Provide a stable funding environment, thereby improving productivity and facilitating nimble, ambitious, creative research; Accelerate scientific innovation by enabling flexibility in pursuing new research directions as they arise, since PD/PIs will not be bound to specific aims proposed in advance of the studies; Reduce the time researchers spend writing grant applications and managing multiple grant awards, thereby allowing more time to be devoted to conducting research; Facilitate PD/PIs commitment to research through increased stability of funding; and Enable PD/PIs to devote more time and energy to mentoring students and junior scientists and providing scientific service.
Funding Opportunity PAR-21-224 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages small business applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing clinical studies. Diseases chosen for study should be based on the NINDS strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm).
Funding Opportunity PAR-21-223 from the NIH Guide for Grants and Contracts. This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. Applicants do not need to be part of the existing NeuroNEXT infrastructure.
Notice NOT-EB-21-016 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-119 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-112 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-238 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from qualified research institutions to seek funds to develop or renovate research facilities that support HIV/AIDS research in areas of basic, translational, clinical, and social and behavioral science research. Targeted are institutions that serve underrepresented and underserved populations or that are in Institutional Development Award (IDeA)-eligible states. Research-intensive institutions are not eligible. The facilities must support research aligned with the NIH-established priorities for HIV/AIDS research. Any request must be justified by current and anticipated future research needs.
Notice NOT-AI-21-048 from the NIH Guide for Grants and Contracts
Notice NOT-EB-21-017 from the NIH Guide for Grants and Contracts
Notice NOT-EB-21-015 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-077 from the NIH Guide for Grants and Contracts
Notice NOT-HD-21-030 from the NIH Guide for Grants and Contracts
Notice NOT-NS-21-049 from the NIH Guide for Grants and Contracts